Once a patient with septic shock has received the first liter, what comes next? ARISE FLUIDS reshapes the ED shock strategy before 30 mL/kg: more fluid or earlier vasopressors?
NephJC Short: 24-Month Iptacopan eGFR Data in IgA Nephropathy
SODa-BIC on Instagram
SODa-BIC on Instagram
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Daniel Ramirez and Urvashi Khan
FIND-CKD trial on Instagram
FIND-CKD on Instagram
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Andreea Manolea
Bonus: more on finerenone in proteinuric CKD universe- visuals by Cristina Popa
TRACK trial on Instagram
TRACK trial on Instagram
A more visual summary of the trial and relevant context (just 6 images to look at!). Infographics by Cristina Popa
Buffering without benefit? The SODa-BIC study
SODa BIC: El Resumen Visual
El bicarbonato quizá no beneficie a todos los pacientes con acidosis metabólica. Tras SODa-BIC, la pregunta ya no es si funciona, sino ¿en qué pacientes podría seguir aportando beneficio?
Revisa el resumen visual creado por Daniel Ramirez #NephJC
SODa BIC: The Visual Abstract
Bicarbonate may not benefit all patients with metabolic acidosis. After SODa-BIC, the question is no longer whether it works, but which patients, might still benefit.
Check out the VA by Daniel Ramirez #NephJC
Beyond Diabetic Kidney Disease: FIND-ing Finerenone's Next Role
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.
FIND CKD: The Visual Abstract
Is finerenone ready to move beyond diabetes?
The FIND-CKD phase 3 arrived from the #ERA26 and is the first one to show kidney protection with finerenone in non-diabetic CKD.
The next challenge is no longer whether finerenone belongs in non-diabetic CKD, but how to best combine with the rest of the pillars to maximize protection.
Check out the newest VA created by our intern Raquel Barba
FIND CKD: El Resumen Visual
¿Está la finerenona lista para ir más allá de la diabetes?
El estudio FIND-CKD recien llegado del #ERA26, es el primer ensayo fase 3 que demuestra protección renal con finerenona en pacientes con ERC no diabética.
El siguiente reto ya no es si la finerenona tiene un lugar en la ERC no diabética, sino cómo combinarla de la mejor manera con el resto de los pilares del tratamiento para maximizar la protección renal.
No se pierdan el nuevo Visual Abstract creado por nuestra interna Raquel Barba
Majesty: The Visual Abstract
Fresh from the #ERA26 Late-Breaking Clinical Trials, the MAJESTY study compared obinutuzumab with tacrolimus and raises important questions about the future of anti-CD20 therapy.
👑 Is deeper B-cell depletion enough to claim the throne?
📖 Check out the latest Visual Abstract by Dr Divya Bajpai
Majesty: El Resumen Visual
Recién llegado desde #ERA26, el estudio MAJESTY comparó obinutuzumab frente a tacrolimus y plantea importantes interrogantes sobre el futuro de las terapias anti-CD20 en la nefropatía membranosa primaria.
👑 ¿Será suficiente una depleción más profunda de células B para reclamar el trono?
📖 Revisa el más reciente resumen visual elaborado por la Dra Divya Bajpai
Heir to the Throne? Obinutuzumab in the membranous nephropathy MAJESTY trial
Making an IMPACT on BP: Why pills alone won't win the war
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
IMPACTS-BP: The Visual Abstract
Can multifaceted strategies improve hypertension control in low-income patients?
Hypertension remains one of the leading cardiovascular risk factors worldwide. However, achieving adequate blood pressure control continues to be a major challenge, especially in low-income populations. The IMPACTS-BP trial has arrived, a study evaluating whether a multifaceted team-based strategy can improve blood pressure control and adherence to antihypertensive therapy.
Check out the VA by Dra Akshaya Jayachandran, and don’t forget to join the live discussion with @NephJC on X and Bluesky
El ensayo IMPACT-BP: El Resumen Visual
¿Puede el trabajo colaborativo mejorar el control de la hipertensión?
La hipertensión arterial continúa siendo uno de los principales factores de riesgo cardiovascular a nivel mundial. Sin embargo, lograr un adecuado control de la presión arterial sigue siendo un desafío, especialmente en poblaciones de bajos ingresos. Hoy aterriza el ensayo IMPACTS-BP, un estudio que evaluó si una estrategia multifacética basada en equipos puede mejorar el control y la adherencia al tratamiento antihipertensivo.
Revisa el resumen visual realizado por la Dra Akshaya Jayachandran y no olvides unirte en vivo con @NephJC en X y Bluesky
